Cellect Biotechnology Ltd (APOP) Stock
APOP is no longer traded. Cellect Biotechnology was delisted from the Nasdaq in November 2021.
Prices on this page are historical; the last trade was November 3, 2021 at $9.87.
Cellect Biotechnology stock price history
APOP final trading statistics
- Final close
- $9.87
- Final trading day
- Nov 3, 2021
- Market cap at delisting
- $9.68M
- Shares outstanding
- 0.98M
- Final 52-week range
- $1.67 – $29.80
- Avg. volume (final 3 mo.)
- 1,829,695
- All-time high (split-adj.)
- $32700.00 · Mar 2017
- All-time low (split-adj.)
- $744.00 · Mar 2020
- Return since IPO
- -90.1%
- Beta
- 1.88
- Book value / share
- $0.69
- Price / book
- 14.28
Cellect Biotechnology annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2020 | $0.00 | -$18.1M | -$6.39 |
| FY2019 | $0.00 | $16.8M | -$6.91 |
| FY2018 | $0.00 | -$20.1M | -$14.44 |
| FY2017 | $0.00 | $28.2M | -$29.20 |
| FY2016 | $0.00 | $15.3M | -$5.33 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Cellect Biotechnology Ltd
As of October 28, 2021, Cellect Biotechnology Ltd. was acquired by Quoin Pharmaceuticals, Inc., in a reverse merger transaction. Cellect Biotechnology Ltd., a biotechnology company, engages in developing ApoGraft, a technology platform that functionally selects stem cells to enhance the safety of regenerative medicine and stem cell therapies in Israel. The company develops ApoTainer, a kit for hematopoietic stem cell transplantation procedures. It has collaborations with the denovoMATRIX group of the Technische Universität Dresden to conduct examinations into the tentative synergy between ApoGraft and denovoMAtrix technology for the purpose of evaluating collaborative development of products for regenerative medicine; Cell2in Inc. to conduct scientific evaluations combining ApoGraft with Cell2in's identification technology FreSHtracer, which monitors stem cell quality by utilizing a fluorescent dye to characterize their oxidative stress state; and XNK therapeutics to focus on the development of cell-based therapeutics from NK cells. The company was formerly known as Cellect Biomed Ltd. and changed its name to Cellect Biotechnology Ltd. in July 2016. Cellect Biotechnology Ltd. was incorporated in 1986 and is headquartered in Kfar Saba, Israel.
Cellect Biotechnology stock FAQ
What happened to Cellect Biotechnology stock?
Cellect Biotechnology stock was delisted from the Nasdaq. Its final close was $9.87 on November 3, 2021.
Is APOP stock still trading?
No. APOP was delisted from the Nasdaq in November 2021 and no longer trades on a U.S. exchange.
What was the last price of APOP stock?
APOP closed at $9.87 on its final trading day, November 3, 2021, for a market value of about $9.68M.
What were Cellect Biotechnology's revenue and earnings in its last full fiscal year?
Cellect Biotechnology reported revenue of $0.00 and net income of -$18.1M in fiscal 2020, its last full year as a public company.
When did Cellect Biotechnology go public?
Cellect Biotechnology Ltd stock began trading on July 29, 2016.